Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Validity of JVA interpretation in conjunction with RDC history & clinical examination to assess TMD,

Go back to Resources

Validity of JVA interpretation in conjunction with RDC history & clinical examination to assess TMD,

Authors:

Location:

Go back to Resources

Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,

Go back to Resources

Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,

Go back to Resources

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,

Authors:

Secondary:

Volume:

Go back to Resources

The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).

Go back to Resources

The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).

Authors:

Secondary:

Pagination:

Go back to Resources

The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women,

Go back to Resources

The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women,

Authors:

Go back to Resources

The progression of myopia in school-age children: data from the Columbia Medical Plan,

Go back to Resources

The progression of myopia in school-age children: data from the Columbia Medical Plan,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

The overlapping coefficient for two normal probability functions with unequal variances.

Go back to Resources

The overlapping coefficient for two normal probability functions with unequal variances.

Authors:

Location:

Go back to Resources

The effects of treatment noncompliance on power in a 2x2 factorial design,

Go back to Resources

The effects of treatment noncompliance on power in a 2x2 factorial design,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

The conversion of kidney transplant patients to tacrolimus from cyclosporine because of refractory rejection or significant cyclosporine toxicity,

Go back to Resources

The conversion of kidney transplant patients to tacrolimus from cyclosporine because of refractory rejection or significant cyclosporine toxicity,

Authors:

Location:

Go back to Resources

Steady improvement in post 1 year half-life of pediatric renal transplants,

Go back to Resources

Steady improvement in post 1 year half-life of pediatric renal transplants,

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 110
  • Page 111
  • Page 112
  • Page 113
  • Current page 114
  • Page 115
  • Page 116
  • Page 117
  • Page 118
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification